MedTrace Logo

Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]

NCT06511193 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2026-05-05

No results posted yet for this study

Summary

The CHRONICLES study will investigate the change in clinical and patient reported outcomes after six-months of treatment with Budenoside/Glycopyrronium/Formoterol \[BGF\] in a real-world setting.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Budenoside/Glycopyrronium/Formoterol

Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria

Sponsors & Collaborators

  • Asthma Research Group Inc.

    collaborator UNKNOWN

  • University Health Network, Toronto

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Eligibility

Min Age
35 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-17
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06511193 on ClinicalTrials.gov